SCHEMBL4833283

SCHEMBL4833283

NC1=c2ccsc2=NCN1c1ccc(NC(=O)/C=C/c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.52
▸ RAB9A P51151 4/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ NPC1 O15118 3/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ MMP1 P03956 7/20 0.47
▸ MMP2 P08253 7/20 0.47
▸ MMP9 P14780 7/20 0.47
▸ EGFR P00533 7/20 0.47
▸ MAOA P21397 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ DEGS1 O15121 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ NFKB2 Q00653 1/20 0.45
▸ RELA Q04206 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.42
▸ TOP2A P11388 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833308 1.00 MAPT (0.52) MAPTRAB9AKMT2ANPC1SMN1; SMN2
SCHEMBL4834149 0.89 MEN1 (0.51) MAPTRAB9AKMT2ANPC1SMN1; SMN2
SCHEMBL4834173 0.89 MEN1 (0.51) MAPTRAB9AKMT2ANPC1SMN1; SMN2
SCHEMBL4835290 0.82 RAB9A (0.49) MAPTRAB9AKMT2ANPC1SMN1; SMN2
SCHEMBL4834603 0.79 BAZ1A (0.41) MAPTKMT2ANPC1SMN1; SMN2MEN1
SCHEMBL4831085 0.77 SCN3A (0.51) RAB9ANPC1SMN1; SMN2DEGS1ALDH1A1
SCHEMBL4828766 0.72 RAB9A (0.47) MAPTRAB9AKMT2ANPC1SMN1; SMN2
SCHEMBL11590995 0.71 EGFR (0.92) KMT2AMEN1MMP1MMP2MMP9
SCHEMBL4831024 0.70 TRPV1 (0.50) MAPTKMT2ANPC1SMN1; SMN2MEN1
SCHEMBL4826352 0.70 IDO1 (0.38) RAB9ANPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MAPT 2499/4885RAB9A 3248/4885KMT2A 324/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MAPT 2424/4885RAB9A 4166/4885KMT2A 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback